A phase 3 study of Tarcocimab-tedromer in non-proliferative Diabetic-retinopathy
Latest Information Update: 17 Mar 2025
At a glance
- Drugs Tarcocimab tedromer (Primary)
- Indications Diabetic retinopathy
- Focus Therapeutic Use
- Acronyms GLOW 1
Most Recent Events
- 10 Mar 2025 Primary endpoint has been met.
- 10 Mar 2025 Results presented in a Kodiak Sciences media release.
- 04 Apr 2024 New trial record